Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Immunohistochemistry
100%
Targeted Therapy
100%
Human Epidermal Growth Factor Receptor 2 (HER2)
100%
Uterine Serous Carcinoma
100%
Chromogenic in Situ Hybridization
75%
Next-generation Sequencing
62%
HER2 Positivity
62%
Tumor
50%
HER2-targeted Therapy
25%
Somatic mutation
12%
Therapeutic Target
12%
Phosphoinositide 3-kinase (PI3K)
12%
Positive Predictive Value
12%
Tumor mutational Burden
12%
Microsatellite Instability-high (MSI-H)
12%
ERBB2 Amplification
12%
Affect Responses
12%
Concordance Rate
12%
Therapy Resistance
12%
HER2 Breast Cancer
12%
Cancer Guidelines
12%
Tumor Registry
12%
Gene Alteration
12%
PD-L1 Expression
12%
HER2 Testing
12%
Fragment Analysis
12%
NextSeq
12%
Agricultural and Biological Sciences
Immunohistochemistry
100%
Targeted Therapy
100%
In Situ Hybridization
75%
Next-Generation Sequencing
62%
Neoplasm
37%
Tumor
37%
Microsatellite
12%
KRAS
12%
Somatic Mutation
12%
PD-L1
12%
Malignant Neoplasm
12%
Nursing and Health Professions
Carcinoma
100%
Immunohistochemistry
100%
In Situ Hybridization
75%
Next-Generation Sequencing
62%
Practice Guideline
50%
Neoplasm
37%
Breast Cancer
12%
Predictive Value
12%
Microsatellite Instability
12%
Therapy Resistance
12%
Biochemistry, Genetics and Molecular Biology
Chromogenic In Situ Hybridization
100%
Targeted Therapy
100%
Next Generation Sequencing
83%
Somatic Mutation
16%
Gene Mutation
16%
KRAS
16%
Microsatellite Instability
16%
PD-L1
16%
Immunology and Microbiology
In Situ Hybridization
100%
Next Generation Sequencing
83%
Gene Mutation
16%
Programmed Death-Ligand 1
16%
Microsatellite Instability
16%
Somatic Mutation
16%
Tumor Mutational Burden
16%
Pharmacology, Toxicology and Pharmaceutical Science
Neoplasm
100%
Carcinoma
100%
Breast Cancer
33%
Therapy Resistance
33%